Wu 2014.

Methods	Type of trial: efficacy trial Allocation: randomised Intervention model: parallel assignment Masking: no blinding Primary purpose: treatment
Participants	Condition: T2DM Enrollment: 93 participants Inclusion criteria: T2DM, FPG levels > 7.8 mmol/L and/or 2‐h PPG > 10.0 mmol/L. Exclusion criteria: T1DM, hypertension, hyperlipidaemia, kidney disease, infection, heart failure, thyroid dysfunction, diabetic ketoacidosis, smoking
Interventions	Intervention(s): metformin (1500 mg/day) Comparator(s): pioglitazone (15 mg/day)
Outcomes	Primary outcome(s): — Secondary outcome(s): — Other outcome(s): glucose, insulin, islet function, vascular endothelial function, plasma endothelin (ET‐1), serum nitric oxide (NO), adverse reactions and liver and kidney function
Study details	Trial identifier: —
Publication details	Language of publication: English Funding: — Publicationstatus: full article / peer‐reviewed journal
Stated aim of study	Quote from publication: "... investigating the effects of metformin on vascular endothelial function in patients with type 2 DM (T2DM)"
Notes	Marked as a study awaiting classification due to it being unclear whether participants continued existing glucose‐lowering drugs during intervention. Trial authors have been contacted.